Inguinal Hernia RepairNCT02537860
Paravertebral Block for Inguinal Hernia Repair in Elderly
A study testing Paravertebral block injections from T12 to L2, Paravertebral block injections between T11 and L3 and Herniorrhaphy in people with Inguinal Hernia Repair, run by Makassed General Hospital at 1 site in Lebanon.
Trial summary
This prospective double-blinded clinical trial is intended to compare three nerve stimulator- guided paravertebral block injections versus five injections for elderly patients undergoing hernia repair regarding intraoperative hemodynamic stability and postoperative pain. Read more about this study
- Who is it for?
- Ages 65 years and older
- Conditions the study is for
- Inguinal Hernia Repair
- What is being tested?
- Paravertebral block injections from T12 to L2, Paravertebral block injections between T11 and L3 and Herniorrhaphy
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 200 participants
- Where
- 1 siteLebanon
- Study dates
- Dec 2015to 30 Dec 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- No healthy volunteers
- Older adult
Who may be able to join
- patients admitted to undergo elective unilateral inguinal hernia repair
- patients with ASA II, III or IV
Who cannot join
- bilateral inguinal hernia
- incarcerated hernia
- emergency cases
- known history of allergic reactions to local anesthesia
- bleeding disorders
- neurological disorders
- infection at site of injection
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Paravertebral Block for Inguinal Hernia Repair in Elderly: Randomized Double-blinded Clinical Trial
This prospective double-blinded clinical trial is intended to compare three nerve stimulator- guided paravertebral block injections versus five injections for elderly patients undergoing hernia repair regarding intraoperative hemodynamic stability and postoperative pain.
Read the detailed description
Introduction
The most effective anesthetic technique for inguinal hernia repair remains a controversial issue; however, paravertebral block (PVB) has resulted in significant postoperative analgesia, less postoperative nausea and vomiting (PONV) and short hospital stay compared to general anesthesia (GA), spinal anesthesia (SA) and ilioinguinal nerve block.
Elderly patients usually have higher risk for developing mental disturbances and cardiopulmonary complications following GA. Hence, elderly patients may benefit from PVB. Although PVB has shown satisfactory outcome; nevertheless, there is no standardized PVB regarding the technique and number of injections.
Based on this background, the objective of this prospective double-blinded study is to compare three nerve stimulator- guided PVB injections versus five injections for elderly patients undergoing hernia repair regarding intraoperative hemodynamic stability and postoperative pain.
Methods Following approval of the Institutional Review Board, written informed consent will be obtained from 200 patients aged above 65 years with ASA II, III or IV admitted to undergo elective unilateral inguinal hernia repair between September 2015 and September 2016.
The sealed envelope technique is used to divide the patients into two groups. Group III (100 patients) will receive three PVB injections from T12 to L2 and placebo at T11 and L3. Group V (100 patients) will receive five PVB injections between T11 and L3. The anesthetist, surgeon, patient and data collector are all blind to the patients' group.
ECG leads, pulse oximetry and non-invasive oscillometric arterial pressure are attached. Patients will be given 1 µg/kg intravenous (IV) fentanyl (Fentanyl Hameln 10 ml, 0.05 mg/ml, Hameln Pharmaceuticals, Germany) as premedication. Unilateral PVB will be performed while the patient is in the lateral decubitus position with the side to be operated being upwards. Sites of injection are marked 2.5-3 cm lateral to the midline of the vertebral column.
Paravertebral block technique Following aseptic preparation of the skin, the injection sites are infiltrated with 0.1 ml of lidocaine 1% each using an 8 mm, 30 G needle (BD Micro-Fine Plus, Becton Dickinson and company, USA). PVB injections are done using a 100 mm 22 G nerve stimulator needle (Stimuplex, B.Braun, Melsungen, Germany). The injections begin at L3 and proceed upwards reaching to T11. The needle is introduced perpendicularly to the skin at the site of the injection point using the following nerve stimulator settings: 5mA, 9V and 2Hz. The stimulating needle is gently manipulated into a position to allow for an adequate muscular response with a stimulating current of 0.4-0.8 mA. Then, the injection is performed. Block onset is determined by cold test and pinprick test.
In order to preserve the double blindness of this clinical trial, two syringes will be used for both groups. The first syringe labeled (A) (20 ml) is filled with 15 mL of solution and used to perform equal injections at the levels T12, L1, and L2 (5mL each). The second syringe labeled (B) (10 ml) is used to inject the solution at the levels T11 and L3 (5 ml each).
To ensure equal anesthetic dose of 75 mg of bupivacaine for each patient, the syringes are prepared as follows:
For group V, both syringes (A) and (B) contain 3mg of bupivacaine/ml whereas for group III, the syringe (A) is prepared with 5 mg bupivacaine/ml while syringe (B) contains placebo.
To allow for adequate blinding, the solution used for injection (saline or local anesthetic mixture) is prepared by an independent nurse outside the operating room.
If a patient feels pain during the surgery, 50 - 100 µg IV fentanyl will be given and followed by 0.4-0.5 mg/kg propofol if needed while keeping the patient responsive to verbal stimulation. If the latter is not sufficient, the patient is converted to GA.
Data Collection Demographic and preoperative variables are collected. Time to perform the block, intraoperative hemodynamic monitoring (MAP and HR) are noted during the entire surgery and recorded pre-incision, at skin incision, at inguinal hernia sac traction, and upon wound closure. Supplemental intraoperative fentanyl and propofol is recorded. Surgery duration, incidence of PONV and numbness are noted.
Patients' satisfaction is also assessed based on their comfort and activity during the procedure, intra- and postoperatively. Patient's comfort is determined by: feeling of pain, PONV, and negative memory of the procedural experience. The patient's activity is based on the ability to sit, move and walk. Patients rate these on a scale of one to three ranging from satisfied, partially satisfied, and unsatisfied. Surgeon's satisfaction is based on the overall intra- and postoperative status of the patient. It is measured based on the following: patient's movement or feeling pain during the operation, self-transportation from the surgical table to stretcher, and postoperative pain.
Postoperative pain is assessed during the first five postoperative days (0 hr, 6 hr, 12 hr, and day 1 till day 5) using the Verbal Numeric Rating Scale (VNRS) (0 no pain and 10 worst possible pain). Patients will be discharged the same day once they had urinated and demonstrated ability to tolerate oral diet. Data will be collected during the hospital stay by residents blind to the patient's group. Patients will be contacted by the same resident during the follow-up period through daily phone calls.
- Conditions
- Inguinal Hernia Repair
- Being tested
- Paravertebral block injections from T12 to L2, Placebo at T11 and L3, Paravertebral block injections between T11 and L3, Herniorrhaphy, Intravenous (IV) fentanyl
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Paravertebral block injections from T12 to L2Other
Three anesthetic injections are done
Placebo at T11 and L3Other
Two injections that contain saline are performed
Paravertebral block injections between T11 and L3Other
Five anesthetic injections are done
HerniorrhaphyProcedure or surgery
Unilateral inguinal hernia repair
Intravenous (IV) fentanylDrug
Patients will be given 1 μg/kg intravenous (IV) fentanyl as premedication
BupivacaineDrug
Each patient will receive 75 mg bupivacaine during PVB
| Study group | Role | What they receive |
|---|---|---|
| Three PVB injections | Experimental | Patients will receive three PVB injections from T12 to L2 and placebo at T11 and L3 Receives: Other: Paravertebral block injections from T12 to L2; Other: Placebo at T11 and L3; Procedure: Herniorrhaphy; Drug: Intravenous (IV) fentanyl; Drug: Bupivacaine |
| Five PVB injections | Experimental | Patients will receive five PVB injections between T11 and L3. Receives: Other: Paravertebral block injections between T11 and L3; Procedure: Herniorrhaphy; Drug: Intravenous (IV) fentanyl; Drug: Bupivacaine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean arterial pressure (MAP) for hemodynamic stability
Measured: Patients will be monitored during the operation, an expected average of 90 minutes
Secondary outcomes (1)
Pain assessed through the Verbal Numeric Rating Scale (VNRS).
Measured: 5 postoperative days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Sep 2015 (estimated)
- Study startDec 2015
- Primary completion30 Dec 2017
- Study completion30 Dec 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Inguinal Hernia RepairStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 200 participants (actual)
Sponsor and investigators
- Lead sponsor
- Makassed General Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Zoher Naja, Makassed General Hospital
- Investigators
- Zoher Naja, Principal investigator, Chairperson of Anesthesia department
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02537860
- Sponsor's protocol ID
- 08252015
- Status last verified
- Jan 2018
- First submitted
- 25 Aug 2015
- Last updated
- 3 Jan 2018
- Results posted
- No
- Data monitoring committee
- No
Publications
Naja Z, Kanawati S, Khatib ZE, Ziade F, Nasreddine R, Naja AS. Three versus five lumbar paravertebral injections for inguinal hernia repair in the elderly: a randomized double-blind clinical trial. J Anesth. 2019 Feb;33(1):50-57. doi: 10.1007/s00540-018-2582-9. Epub 2018 Nov 16.
PubMed 30446826
Study at a glance
From the registry record, last updated by the sponsor on 3 Jan 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Paravertebral Block for Inguinal Hernia Repair in Elderly: Randomized Double-blinded Clinical Trial
- ClinicalTrials.gov ID
- NCT02537860
- Acronym / sponsor ID
- 08252015
- Conditions
- Inguinal Hernia Repair
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 200 participants (actual)
- Lead sponsor
- Makassed General HospitalUniversity, hospital or other
- Study start
- Dec 2015
- Primary completion
- 30 Dec 2017 (actual)
- Study completion
- 30 Dec 2017 (actual)
- First posted
- 2 Sep 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This prospective double-blinded clinical trial is intended to compare three nerve stimulator- guided paravertebral block injections versus five injections for elderly patients undergoing hernia repair regarding intraoperative hemodynamic stability and postoperative pain.
Detailed description
Introduction
The most effective anesthetic technique for inguinal hernia repair remains a controversial issue; however, paravertebral block (PVB) has resulted in significant postoperative analgesia, less postoperative nausea and vomiting (PONV) and short hospital stay compared to general anesthesia (GA), spinal anesthesia (SA) and ilioinguinal nerve block.
Elderly patients usually have higher risk for developing mental disturbances and cardiopulmonary complications following GA. Hence, elderly patients may benefit from PVB. Although PVB has shown satisfactory outcome; nevertheless, there is no standardized PVB regarding the technique and number of injections.
Based on this background, the objective of this prospective double-blinded study is to compare three nerve stimulator- guided PVB injections versus five injections for elderly patients undergoing hernia repair regarding intraoperative hemodynamic stability and postoperative pain.
Methods Following approval of the Institutional Review Board, written informed consent will be obtained from 200 patients aged above 65 years with ASA II, III or IV admitted to undergo elective unilateral inguinal hernia repair between September 2015 and September 2016.
The sealed envelope technique is used to divide the patients into two groups. Group III (100 patients) will receive three PVB injections from T12 to L2 and placebo at T11 and L3. Group V (100 patients) will receive five PVB injections between T11 and L3. The anesthetist, surgeon, patient and data collector are all blind to the patients' group.
ECG leads, pulse oximetry and non-invasive oscillometric arterial pressure are attached. Patients will be given 1 µg/kg intravenous (IV) fentanyl (Fentanyl Hameln 10 ml, 0.05 mg/ml, Hameln Pharmaceuticals, Germany) as premedication. Unilateral PVB will be performed while the patient is in the lateral decubitus position with the side to be operated being upwards. Sites of injection are marked 2.5-3 cm lateral to the midline of the vertebral column.
Paravertebral block technique Following aseptic preparation of the skin, the injection sites are infiltrated with 0.1 ml of lidocaine 1% each using an 8 mm, 30 G needle (BD Micro-Fine Plus, Becton Dickinson and company, USA). PVB injections are done using a 100 mm 22 G nerve stimulator needle (Stimuplex, B.Braun, Melsungen, Germany). The injections begin at L3 and proceed upwards reaching to T11. The needle is introduced perpendicularly to the skin at the site of the injection point using the following nerve stimulator settings: 5mA, 9V and 2Hz. The stimulating needle is gently manipulated into a position to allow for an adequate muscular response with a stimulating current of 0.4-0.8 mA. Then, the injection is performed. Block onset is determined by cold test and pinprick test.
In order to preserve the double blindness of this clinical trial, two syringes will be used for both groups. The first syringe labeled (A) (20 ml) is filled with 15 mL of solution and used to perform equal injections at the levels T12, L1, and L2 (5mL each). The second syringe labeled (B) (10 ml) is used to inject the solution at the levels T11 and L3 (5 ml each).
To ensure equal anesthetic dose of 75 mg of bupivacaine for each patient, the syringes are prepared as follows:
For group V, both syringes (A) and (B) contain 3mg of bupivacaine/ml whereas for group III, the syringe (A) is prepared with 5 mg bupivacaine/ml while syringe (B) contains placebo.
To allow for adequate blinding, the solution used for injection (saline or local anesthetic mixture) is prepared by an independent nurse outside the operating room.
If a patient feels pain during the surgery, 50 - 100 µg IV fentanyl will be given and followed by 0.4-0.5 mg/kg propofol if needed while keeping the patient responsive to verbal stimulation. If the latter is not sufficient, the patient is converted to GA.
Data Collection Demographic and preoperative variables are collected. Time to perform the block, intraoperative hemodynamic monitoring (MAP and HR) are noted during the entire surgery and recorded pre-incision, at skin incision, at inguinal hernia sac traction, and upon wound closure. Supplemental intraoperative fentanyl and propofol is recorded. Surgery duration, incidence of PONV and numbness are noted.
Patients' satisfaction is also assessed based on their comfort and activity during the procedure, intra- and postoperatively. Patient's comfort is determined by: feeling of pain, PONV, and negative memory of the procedural experience. The patient's activity is based on the ability to sit, move and walk. Patients rate these on a scale of one to three ranging from satisfied, partially satisfied, and unsatisfied. Surgeon's satisfaction is based on the overall intra- and postoperative status of the patient. It is measured based on the following: patient's movement or feeling pain during the operation, self-transportation from the surgical table to stretcher, and postoperative pain.
Postoperative pain is assessed during the first five postoperative days (0 hr, 6 hr, 12 hr, and day 1 till day 5) using the Verbal Numeric Rating Scale (VNRS) (0 no pain and 10 worst possible pain). Patients will be discharged the same day once they had urinated and demonstrated ability to tolerate oral diet. Data will be collected during the hospital stay by residents blind to the patient's group. Patients will be contacted by the same resident during the follow-up period through daily phone calls.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Three PVB injections | Experimental | Other: Paravertebral block injections from T12 to L2, Other: Placebo at T11 and L3, Procedure: Herniorrhaphy, Drug: Intravenous (IV) fentanyl, Drug: BupivacainePatients will receive three PVB injections from T12 to L2 and placebo at T11 and L3 |
| Five PVB injections | Experimental | Other: Paravertebral block injections between T11 and L3, Procedure: Herniorrhaphy, Drug: Intravenous (IV) fentanyl, Drug: BupivacainePatients will receive five PVB injections between T11 and L3. |
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
Key inclusion criteria (2 listed)
- patients admitted to undergo elective unilateral inguinal hernia repair
- patients with ASA II, III or IV
Key exclusion criteria (7 listed)
- bilateral inguinal hernia
- incarcerated hernia
- emergency cases
- known history of allergic reactions to local anesthesia
- bleeding disorders
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Paravertebral block injections from T12 to L2Three anesthetic injections are done | Other | Three PVB injections |
| Placebo at T11 and L3Two injections that contain saline are performed | Other | Three PVB injections |
| Paravertebral block injections between T11 and L3Five anesthetic injections are done | Other | Five PVB injections |
| HerniorrhaphyUnilateral inguinal hernia repair | Procedure or surgery | Five PVB injections, Three PVB injections |
| Intravenous (IV) fentanylPatients will be given 1 μg/kg intravenous (IV) fentanyl as premedication | Drug | Five PVB injections, Three PVB injections |
| BupivacaineEach patient will receive 75 mg bupivacaine during PVB | Drug | Five PVB injections, Three PVB injections |
Primary outcome
Mean arterial pressure (MAP) for hemodynamic stability
Time frame: Patients will be monitored during the operation, an expected average of 90 minutes
1 secondary outcome
Pain assessed through the Verbal Numeric Rating Scale (VNRS).
Time frame: 5 postoperative days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Jan 2018.
- Derived from this study: PubMed 30446826Naja Z, Kanawati S, Khatib ZE, Ziade F, Nasreddine R, Naja AS. Three versus five lumbar paravertebral injections for inguinal hernia repair in the elderly: a randomized double-blind clinical trial. J Anesth. 2019 Feb;33(1):50-57. doi: 10.1007/s00540-018-2582-9. Epub 2018 Nov 16.
Related trials for Inguinal Hernia Repair
Recruiting
Desarda Tissue Technique vs Lichtenstein Technique for Primary Inguinal Hernia Repair
Inguinal Hernia Unilateral, Complications of Surgical Procedures or Medical Care
Recruiting
Comparison of Two Surgical Techniques for Indirect Inguinal Hernia Repair
Indirect Inguinal Hernia
Recruiting
Permanent Versus Slowly Dissolving Stitches for Non-Mesh (Shouldice) Groin Hernia Repair
Inguinal Hernia
Active, not recruiting
Urinary Catheterization Versus No Catheterization in Laparoscopic Total Extraperitoneal Inguinal Hernia Repair
Inguinal Hernias
Recruiting
Effect of Anterior Iliac Block on Postoperative Analgesia and Patient Satisfaction in Inguinal Hernia Repair Surgery
Anterior Ilıac Block, Hernia Surgery
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Zoher Naja principal investigator
Chairperson of Anesthesia department
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Paravertebral block injections from T12 to L2, Paravertebral block injections between T11 and L3 and Herniorrhaphy in people with Inguinal Hernia Repair, run by Makassed General Hospital at 1 site in Lebanon.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Jan 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Lebanon. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean arterial pressure (MAP) for hemodynamic stability (time frame: Patients will be monitored during the operation, an expected average of 90 minutes). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02537860, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Jan 2018.